Session: MP15: Infections/Inflammation/Cystic Disease of the Genitourinary Tract: Prostate & Genitalia
MP15-20: Urinary tract infection after radiation therapy or radical prostatectomy on prognosis of patients with prostate cancer: a population-based study
Introduction: We assessed the trends in urinary tract infections (UTIs) and prognosis of patients with prostate cancer after radical prostatectomy (RP) and radiation therapy (RT) as definitive treatment options. Methods: The data of patients diagnosed with prostate cancer between 2007 and 2016 were collected using the National Health Insurance Service database. The incidence of UTIs was evaluated in patients treated with RT, open/laparoscopic RP, and robot-assisted RP. Cox proportional hazard analysis and Kaplan–Meier analysis were performed to assess survival. Results: In total, 28,887 patients received definitive treatment. In the acute phase ( <3 months), RP was associated with more frequent UTIs than RT; however, in the chronic phase (>12 months), RT was associated with more frequent UTIs than RP. The standardized incidence ratios were 2.47 for upper UTIs and 3.04 for lower UTIs. Open/laparoscopic RP was associated with a higher risk of UTIs than RT, whereas robot-assisted RP was not. In the patients with UTIs, the year of PC diagnosis, Charlson Comorbidity Index score, primary treatment, age at UTI diagnosis, type of UTI, hospitalization, and sepsis from UTI were risk factors for overall survival. Conclusions: In patients treated with RP or RT, the incidence of UTIs was higher than that in the general population. The frequency of UTIs differed between patients treated with RP and RT. Open/laparoscopic RP was associated with a higher risk of UTIs than RT, whereas robot-assisted RP was not. UTI characteristics may be related to a poor prognosis. SOURCE OF Funding: This research was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT & Future Planning (NRF-2022R1F1A1076502 & NRF-2022R1A2C2008207).
